James Parsons
Director/Board Member at DIAMEDICA THERAPEUTICS INC.
Net worth: 277 626 $ as of 2024-03-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Matthew Coffey | M | - | 13 years | |
Rick Pauls | M | 52 | 19 years | |
Deborah Brown | F | - | 7 years | |
Scott Kellen | M | 59 | 6 years | |
Wayne Pisano | M | 69 | 11 years | |
Andrew Muratore | M | - | 3 years | |
Deborah Baron | F | 55 | 3 years | |
Brett Whalen | M | - | 1 years | |
Kirk Look | M | - | 21 years | |
David Wambeke | M | - | 1 years | |
Cynthia Pussinen | F | - | 1 years | |
Frank Shannon | M | - | 3 years | |
Richard Pilnik | M | 67 | 15 years | |
Charles Semba | M | 64 | 3 years | |
Julie VanOrsdel Daves | F | - | - | |
Angela Holtham | F | 73 | 10 years | |
Michael Giuffre | M | 68 | 14 years | |
Bernd Seizinger | M | 67 | 9 years | |
Tanya Lewis | F | 53 | 1 years | |
Paul Papi | M | - | 8 years | |
Steven Sangha | M | - | 1 years | |
Delfina Siroen | F | - | - | |
Dominic Cundari | M | - | 2 years | |
Modestus Obochi | M | - | 1 years | |
Richard Kuntz | M | 66 | 1 years | |
Thomas Heineman | M | - | 4 years | |
Kathleen Large | F | 64 | 5 years | |
Jonathan Rigby | M | 56 | 2 years | |
Lorianne K. Masuoka | M | 62 | - | |
Jon Patton | M | - | 4 years | |
Christopher Barnes | M | - | - | |
Daniel Mahony | M | - | 2 years | |
Patricia Andrews | F | 66 | - | |
Ambarish Shah | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
David Allan | M | 82 | 7 years | |
Philip Toleikis | M | - | 15 years | |
Robert Gundel | M | - | 5 years | |
Robert A. Uger | M | 53 |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | 8 years |
Niclas Stiernholm | M | - | 8 years | |
Frank Holler | M | 67 | 9 years | |
Robert L. Kirkman | M | 75 | 8 years | |
Calvin Stiller | M | 83 | 8 years | |
Jan Skvarka | M | 57 | 2 years | |
George Adams | M | 76 | 5 years | |
Michael G. Moore | M | - |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | 16 years |
Philippe Couillard | M | 67 | 3 years | |
Rodney D. Gloss | M | 67 | 6 years | |
Dawson J. Reimer | M | 53 | 5 years | |
Janet Clennett | F | - | - | |
Luke Beshar | M | 65 | 7 years | |
R. Dean Peterson | M | - | 4 years | |
Zhen Yu Xiao | M | 50 | - | |
Penka Petrova | M | 56 | 8 years | |
Aziz Mekouar | M | - | - | |
Scott Myers | M | 57 | - | |
Todd A. Verdoorn | M | 63 | 3 years | |
Helena Tayton-Martin | M | 57 | 4 years | |
Mark Williams | M | 52 | 11 years | |
Scott Duncan | M | - |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | - |
Paul Walker | M | 49 | 1 years | |
Mark Robbins | M | - | 3 years | |
Amy Burroughs | F | 54 | 2 years | |
Raafat E. F. Fahim | M | 70 | 1 years | |
Thomas Reynolds | M | 65 | 7 years | |
Jeffrey Bacha | M | 56 | 14 years | |
Paolo Pucci | M | 63 | 1 years | |
Michael Kamarck | M | 73 | 1 years | |
Mohammad Azab | M | 68 | 2 years | |
Graham Strachan | M | 85 | 5 years | |
Michael R. Sonnenreich | M | 85 | 6 years | |
Walter P. von Wartburg | M | 84 | 4 years | |
James DeMesa | M | 66 | 9 years | |
Leonard Kruimer | M | 66 | 3 years | |
Rosemary Harrison | M | 41 | 1 years | |
Hans P. Black | M | 71 | 8 years | |
Bill Lambert | M | 72 | 4 years | |
Mickey M. Yaksich | M | - | - | |
Bruce A. Weber | M | - | 7 years | |
Ingmar Bruns | M | 49 | 1 years | |
Abdelmalik Slassi | M | 62 | 3 years | |
John Savage | M | - | - | |
Benjamin Looker | M | 42 | - | |
Sydney A. Gilman | M | 72 | - | |
Brian Jahns | M | - | - | |
Yaping Shou | M | - | 2 years | |
Alan A. Steigrod | M | 86 | - | |
Ted Kolodka | M | - | - | |
Lihor A. Simkevitz | F | - | 1 years | |
Beverly Incledon | M | - | - | |
Albert Agro | M | 59 | - | |
Michael J. Gresser | M | - |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | 4 years |
Eric Sievers | M | 60 | 3 years | |
Geoffrey Collett | M | - | 3 years | |
Catherine Mackey | M | 68 | - | |
David Swetlow | M | - | 5 years | |
Peter Murray | M | - | - | |
Don B. Rix | M | 93 | - | |
Michael Berendt | M | 75 |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | 6 years |
Kirsten Gruis | M | - | 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
Canada | 76 | 76.77% |
United States | 24 | 24.24% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- James Parsons
- Personal Network